CMMB vs. PYXS, MCRB, BMEA, ABOS, RENB, INZY, VTVT, RANI, ANRO, and MGX
Should you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Pyxis Oncology (PYXS), Seres Therapeutics (MCRB), Biomea Fusion (BMEA), Acumen Pharmaceuticals (ABOS), Renovaro (RENB), Inozyme Pharma (INZY), vTv Therapeutics (VTVT), Rani Therapeutics (RANI), Alto Neuroscience (ANRO), and Metagenomi (MGX). These companies are all part of the "pharmaceutical products" industry.
Chemomab Therapeutics vs.
Pyxis Oncology (NASDAQ:PYXS) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership, community ranking and media sentiment.
Pyxis Oncology currently has a consensus price target of $9.20, indicating a potential upside of 767.92%. Chemomab Therapeutics has a consensus price target of $9.00, indicating a potential upside of 587.02%. Given Pyxis Oncology's higher possible upside, equities research analysts clearly believe Pyxis Oncology is more favorable than Chemomab Therapeutics.
In the previous week, Pyxis Oncology and Pyxis Oncology both had 2 articles in the media. Pyxis Oncology's average media sentiment score of 0.96 beat Chemomab Therapeutics' score of 0.94 indicating that Pyxis Oncology is being referred to more favorably in the media.
Pyxis Oncology received 11 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. Likewise, 83.33% of users gave Pyxis Oncology an outperform vote while only 65.52% of users gave Chemomab Therapeutics an outperform vote.
Pyxis Oncology has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 46.0% of Chemomab Therapeutics shares are owned by institutional investors. 9.8% of Pyxis Oncology shares are owned by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Chemomab Therapeutics has lower revenue, but higher earnings than Pyxis Oncology. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
Pyxis Oncology's return on equity of -36.22% beat Chemomab Therapeutics' return on equity.
Summary
Pyxis Oncology beats Chemomab Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Chemomab Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chemomab Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CMMB) was last updated on 4/26/2025 by MarketBeat.com Staff
Buy CMMB Stock Free CMMB Stock Alerts